SURVYR

QGEN

Qiagen N.V.
$50.33
+$0.16 (0.32%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-33%-19%-6%+7%+21%Oct 2025Oct 2026Apr 202652w high $57.8252w low $32.53
QGENSPY
Wall St. Highest PT $55.00 (+9.3%) Wall St. Avg PT $48.57 (-3.5%)
$32$38$44$51$57POC $45Hi $55Avg $49
Underwater Drawdown %Max DD -41.4%Current -8.8%
0.0%-41.4%
Relative Strength vs SPY-9.0% vs SPYUnderperforming
+48%0%-48%
1W
+$0.33 (0.66%)
1M
+$5.32 (11.82%)
3M
+$8.52 (20.38%)
6M
+$17.02 (51.10%)
YTD
+$5.76 (12.93%)
1Y
+$2.81 (5.91%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
11 analysts · mean score 2.83
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$50.33
Average target$48.57
−$1.76 (−3.5%) downsideaverage target vs current price
CurrentAverageMedian
Low$40.00
Median$48.57
High$55.00
12-month Wall Street target range
Recent analyst rating changes · 30
Downgrade
2026-10-22 · JP Morgan downgraded QGEN from Overweight to Neutral
Reiterated
2026-10-22 · Baird reiterated Outperform on QGEN
Reiterated
2026-10-14 · JP Morgan reiterated Overweight on QGEN
Upgrade
2026-10-06 · Barclays upgraded QGEN from Equal-Weight to Overweight
Reiterated
2026-09-09 · UBS reiterated Neutral on QGEN
Reiterated
2026-08-10 · Citigroup reiterated Neutral on QGEN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$10.4B
P/E (last 12 months)25.6
P/E (next 12 months, estimated)19.3
52-week range$32.53 – $57.82
Revenue growth (latest quarter vs a year ago)+0.3%
Dividend yield0.70%
Analyst consensusHold (11)
Average analyst price target$48.57 (-4%)

What they do

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for QGEN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

QGEN earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus$0.63 range $0.61–$0.65
Revenue consensus$538.3M 8 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026$0.60est $0.60+0.1%In line with estimates
May 5, 2026$0.54est $0.540.0%In line with estimates
Feb 4, 2026$0.62est $0.62+0.1%In line with estimates
Nov 4, 2025$0.64est $0.62+4.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 23:25:21 ET
24-1125-0225-0525-0825-1126-0226-0526-080.000.65
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$535.0M+0.3%
2026-03-31$492.3M–
2025-12-31$540.4M–
2025-09-30$532.6M–
2025-06-30$533.5M–

Recent dividends

2026-07-07: $0.350 · 2025-07-02: $0.250 · 2024-01-30: $1.358 · 2017-01-25: $1.154 · 2002-12-27: $0.030 · 2002-12-26: $0.002

News & catalysts

More news
Single-Cell eQTL Clinical Workflows Market Forecast to Reach $4.51 Billion by 2030 | Capitalize on 19.9% CAGR with Illumina, QIAGEN, 10x Genomics, Singleron and More
GlobeNewswire · 2h ago
Long-Read Full-Length cDNA Sequencing Global Market Report 2026 | Capitalize on 18.9% CAGR and Single-Cell Demand With PacBio, Oxford Nanopore, 10x Genomics and QIAGEN
GlobeNewswire · 3h ago
Rating changes
Downgrade
2026-10-22 · JP Morgan downgraded QGEN from Overweight to Neutral
Reiterated
2026-10-22 · Baird reiterated Outperform on QGEN
Reiterated
2026-10-14 · JP Morgan reiterated Overweight on QGEN
Upgrade
2026-10-06 · Barclays upgraded QGEN from Equal-Weight to Overweight
Reiterated
2026-09-09 · UBS reiterated Neutral on QGEN
Reiterated
2026-08-10 · Citigroup reiterated Neutral on QGEN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-23 23:25:21 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026